Pharmaceutic-technological and biopharmaceutical aspects in HIV protease inhibitors;Pharmazeutisch-technologische und biopharmazeutische aspekte bei HIV-protease-inhibitoren

Pharmazie in Unserer Zeit

Volumn 30, Issue 3, 2001, Pages 234-239

  Leopold, Claudia S ^a  

^a Pharmazeutische Technologie   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG METABOLISM; DRUG PENETRATION; DRUG TARGETING; FIRST PASS EFFECT; NONHUMAN; PHARMACEUTICAL ENGINEERING; CHEMISTRY; HUMAN; PHARMACEUTICS; REVIEW;

BIOPHARMACEUTICS; DRUG COMPOUNDING; HIV PROTEASE INHIBITORS; HUMANS; TECHNOLOGY, PHARMACEUTICAL;

EID: 0034970649     PISSN: 00483664     EISSN: None     Source Type: Journal    
DOI: 10.1002/1615-1003(200105)30:3<234::AID-PAUZ234>3.0.CO;2-T     Document Type: Article

References (15)

1. Oral absorption of the HIV protease inhibitors: A current update
2. Regiospecific intestinal absorption of the HIV protease inhibitor L-735,524 in beagle dogs
3. Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral absorption
4. "Targeted Delivery" in den Gastrointestinaltrakt
5. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
6. P-glycoprotein, secretory transport, and other barriers to the oral delivery of anti-HIV drugs
7. Comparison of solutol HS 15, Cremophor EL and novel ethoxylated fatty acid surfactants as multidrug resistance modification agents
8. Bile acid inhibition of P-glycoprotein-mediated transport in multidrug-resistant cells and rat liver canalicular membrane vesicles
9. The barrier function of CYP3A4 and P-glycoprotein in the small bowel
10. The pharmacokinetics of combination therapy with nelfinavir plus nevirapine
11. Role of pharmacokinetics in the discovery and development of indinavir
12. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man
13. Mechanism-based inactivation of human cytochrome P450 3A4 by grapefruit juice and red wine
14. Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults